CC
ENTA icon

Corton Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Corton Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,921
Closed -$76.8K – 363
2025
Q1 		$76.8K Buy
+13,921
New +$86K 0.25% 148
2024
Q4 		– Sell
-13,116
Closed -$136K – 459
2024
Q3 		$136K Buy
+13,116
New +$172K 0.07% 427

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corton Capital's ENTA Position: Q2 2025 in Review

Corton Capital sold out of Enanta Pharmaceuticals (ENTA) in Q2 2025, closing a stake of 13,921 shares — an estimated $76.8K sold.

Corton Capital first reported a position in ENTA in Q3 2024 and held it in 2 quarters. The position peaked at $136K in Q3 2024. 107 funds tracked by Wall St. Rank hold ENTA as of Q2 2025.

  • Corton Capital reported no remaining Enanta Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corton Capital sold 13,921 Enanta Pharmaceuticals shares in Q2 2025, an estimated $76.8K.
  • Corton Capital first reported a position in Enanta Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Corton Capital's Enanta Pharmaceuticals position peaked at $136K in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2025.

Based on Corton Capital's 13F filing for Q2 2025, filed 5 Aug 2025.